Solon Ventures

Fever is a technology company that operates a live-entertainment discovery platform. Its primary business is to help users find and book unique, local events and experiences in their cities. Fever's platform curates and personalizes event listings based on user preferences, covering a wide range of activities such as immersive art exhibitions, interactive theater, music concerts, and unique pop-ups. The company aims to make culture and entertainment more accessible, while also supporting local creators by providing them with data and technology to help grow their events.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.

Xceleron, founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, specializes in bioanalytical accelerator mass spectrometry (AMS) services for drug development. The company pioneered human microdose and microtracer techniques to assess the pharmacokinetics and metabolism of developmental drugs during Phase 0, Phase I, and Phase II/III clinical trials. By focusing on micro-dosing and pre-clinical evaluations, Xceleron effectively conducts intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. The company's expertise is particularly beneficial given the challenges posed by contemporary small molecules, which often exhibit low solubility and long half-lives, making early pharmacokinetic and metabolic characterization essential for cost-effective clinical advancement. Driven by a commitment to integrity and scientific collaboration, Xceleron aims to facilitate the rapid and affordable delivery of life-changing products to those in need.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.

Mobcast was founded in 2007 by CEO Tony Lynch and bestselling author Andy McNab. With the rise in the capabilities of mobile phones they spotted an opportunity to develop an online retail platform for digital books on these devices. They recognised the potential of gaining access to large customer bases and billing infrastructures through partnerships with mobile network operators, equipment manufacturers and retailers.

Concentra Analytics was formed in 2008 to bring data science to management practice in a sustainable way. Concentra Analytics builds Software as a Service ("SaaS") data solutions that enable businesses to capture, manage and use data to analyse and transform their operations. A two-time winner at the Corporate Vision Technology Innovator Awards, in 2016 it was named the 'Most Innovative Business Analytics Company' and its flagship product, OrgVue, was awarded 'Best Strategic HR Product' as well as voted a 'Gartner Cool Vendor in Human Capital Management'. Alongside OrgVue, Concentra's other products include SupplyVue for holistic supply chain optimisation and DataPlus, an enterprise data warehouse automation platform. Concentra's analytics and domain experts also leverage best-in-class technologies to build data-driven solutions in functional operational reporting and customer analytics.

Nimbus makes life at work easier, faster and more valuable for millions of people. Since its inception in 1997, Nimbus has helped over 700 organizations - including: Astrazeneca, Barclays Capital, HSBC, JPMorgan, RBS, Sara Lee, Toyota, and ThyssenKrupp.

Gaming Technology Solutions (GTS) is a prominent global provider of gaming solutions tailored for online gaming operations. Established in 2005, the company specializes in delivering games through its open EdGE platform. GTS is licensed as a software provider by the UK government and exclusively offers its solutions to licensed gaming operators that accept bets from legal jurisdictions. In December 2009, GTS was acquired by Playtech, enhancing its capacity to supply open gaming services to over 90 internet operators worldwide. The company's commitment to compliance and quality positions it as a key player in the gaming technology sector.

Peakdale Molecular is a contract research organization. It provides drug discovery services to the pharmaceutical, biotech, diagnostics, and materials sciences industries. They operate a comprehensive suite of services for hit-to-lead and lead optimization studies, including early stage ADME. It offers a variety of customized commercial frameworks, from simple fee-for-service to long-term FTE projects. The company provides services such as drug discovery support, nucleoside chemistry, materials chemistry, research support, and business models. Peakdale Molecular was founded in 1992 and is headquartered in High Peak, Derbyshire.

Founded in 2006, Novalia specializes in creating thin, self-adhesive touch sensors using printed conductive ink and silicon microcontrollers. Based in Cambridge, UK, the company designs bespoke interactive solutions that connect brands with audiences across various sectors such as out-of-home advertising, magazines, retail, direct mail, and music.